EUVIMEDEUVIMED entdecken
Open Access

Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells

Burcin Altun, Gexin Zhao, Baomei Wang, Xuming Mao, Silvio Manfredo-Vieira, Elinor Willis, Enrico Radaelli, Emma E Goodman, Alina C Boesteanu, Saar I Gill, Darshil R Patel, Steven Wong und 3 weitere

Kidney International · 2026-01 · 109 (1) · 89-100

DOI: 10.1016/j.kint.2025.09.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2026-01. Verfasst von Burcin Altun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, B-Lymphocytes, Autoantibodies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Irving Medical Center, Columbia University, Boston University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, driven by autoantibodies that target PLA2R on kidney podocytes. Antibody-based therapy with rituximab induces broad B-cell depletion but is associated with risks of serious infection and reduced efficacy in patients with high proteinuria. Here, we determined the feasibility of developing chimeric autoantibody receptor T-cell (CAART) therapy for PLA2R-specific B-cell depletion in PLA2R MN. METHODS: PLA2R-CAART was produced by T-cell lentiviral transduction. In vitro cytotoxicity and specificity were evaluated against B-cell lines targeting PLA2R immunodominant epitopes and primary PLA2R MN B cells. Adsorption of PLA2R MN IgG was evaluated to determine the extent of pathogenic autoantibody targeting by candidate PLA2R-CAART designs. Specific cytotoxicity, engraftment capability, and off-target toxicity were evaluated in a xenografted anti-PLA2R Nalm-6 preclinical mouse model, with additional toxicology screening by human membrane proteome arrays. RESULTS: We engineered CAARTs targeting key PLA2R epitopes to selectively deplete autoreactive B cells. C17- and C178-CAART (encompassing CysR, CTLD1, and CTLD7, with/without CTLD8 domains) were successfully expressed on primary T cells and demonstrated specific in vitro cytotoxicity against anti-PLA2R B-cell lines targeting CysR, CTLD1, and CTLD7 epitopes. In co-incubation assays with primary B cells or plasma from patients with MN, C17- and C178-CAART significantly reduced anti-PLA2R B cells and adsorbed 69-97% of plasma anti-PLA2R antibody reactivity. In vivo, C17- and C178-CAART treatment in the Nalm-6 xenograft model resulted in significant reduction in target cell outgrowth with C17-CAART showing slight but consistently increased cytotoxic activity. Specificity testing through comprehensive in vivo pathologic analysis and a high-throughput membrane proteome array analysis showed no significant off-target binding for either C17- or C178-CAART. CONCLUSIONS: Our findings establish preclinical proof-of-concept for the therapeutic potential of antigen-specific B-cell depletion by PLA2R-CAART. Additional studies are required to determine clinical feasibility of PLA2R-CAART for PLA2R MN therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousReceptors, Phospholipase A2B-LymphocytesAutoantibodiesLymphocyte DepletionT-LymphocytesReceptors, Chimeric AntigenImmunotherapy, AdoptiveAnimalsHumansMiceDisease Models, Animal

Stichwörter der Autor:innen

autoimmunitycell therapychimeric antigen receptorkidneynephrology

Substanzen

Receptors, Phospholipase A2AutoantibodiesPLA2R1 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Dermatology, Columbia University, New York, New York, USA.
  • Department of Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Cabaletta Bio, Philadelphia, Pennsylvania, USA.
  • Department of Dermatology, Columbia University, New York, New York, USA. Electronic address: asp2261@cumc.columbia.edu.

Förderung

  • NCI NIH HHS
  • Irving Medical Center, Columbia University
  • Boston University
  • University of Pennsylvania
  • National Cancer Institute
  • Abramson Cancer Center
  • Cabaletta Bio
  • National Institutes of Health

Zitieren

APA

Altun, B., Zhao, G., Wang, B., Mao, X., Manfredo-Vieira, S., Willis, E., Radaelli, E., Goodman, E. E., Boesteanu, A. C., Gill, S. I., Patel, D. R., Wong, S., Cottman-Thomas, E., Hogan, J. J., & Payne, A. S. (2026). Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells. Kidney International, 109(1), 89-100. https://doi.org/10.1016/j.kint.2025.09.028

Vancouver

Altun B, Zhao G, Wang B, Mao X, Manfredo-Vieira S, Willis E, et al. Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells. Kidney International. 2026;109(1):89-100. doi:10.1016/j.kint.2025.09.028

BibTeX
@article{Altun2026,
  author = {Altun, Burcin and Zhao, Gexin and Wang, Baomei and Mao, Xuming and Manfredo-Vieira, Silvio and Willis, Elinor and Radaelli, Enrico and Goodman, Emma E and Boesteanu, Alina C and Gill, Saar I and Patel, Darshil R and Wong, Steven and Cottman-Thomas, Ebony and Hogan, Jonathan J and Payne, Aimee S},
  title = {Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells},
  journal = {Kidney International},
  year = {2026},
  volume = {109},
  number = {1},
  pages = {89--100},
  doi = {10.1016/j.kint.2025.09.028}
}
Kostenlos starten →